The Cochlear Limited (ASX: COH) share price is edging lower today as the company announced it has been denied an appeal rehearing in its US patent infringement case.
While the S&P/ASX 200 Index (ASX: XJO) is currently storming 1.92% higher on the back of COVID-19 vaccine news, the Cochlear share price is down 2.54% for the day at $184.21.
Previous developments
This morning’s announcement relates to Cochlear’s ongoing court battle with Alfred E. Mann Foundation for Scientific Research (AMF) and Advanced Bionics (AB).
In November 2018, the US District Court in Los Angeles ruled against Cochlear and awarded damages totalling approximately US$268.1 million to AMF and AB. The company appealed this decision soon after.
Prior to this, the case had been dragging on for years. Back in 2014, a jury found that a group of Cochlear’s implants, sound processors, and software infringed 2 of AMF’s patents. Since then, there have been numerous rulings in favour and against Cochlear.
The result of the appeal of the November 2018 decision was finally handed down in March this year, with the US Court of Appeals for the Federal Circuit in Washington D.C. affirming the previous decision. As such, the court ordered the Cochlear to pay the US$268 million of damages to AMF and AB.
At the time of the announcement, the company stated in an ASX release it would “seek an en banc review by the full Court of Appeals in a petition for a rehearing”.
What did Cochlear announce today?
This morning, the company revealed that the US Court of Appeals had denied its petition for a rehearing of the appeal.
The judgement will become final on 26 May 2020 and Cochlear will now pay approximately US$280 million, which includes post-judgment interest. The company noted that it has committed loan facilities available to fund the payment.
Meanwhile, a decision is still pending in the US District Court on AMF and AB’s application for pre-judgment interest of US$123 million and attorney fees of $15 million. Cochlear has opposed both applications and the associated calculation methodology for the amounts.
As there is significant uncertainty over whether Cochlear will be forced to make these payments, the company is treating this exposure as a contingent liability on its balance sheet.
NEW. The Motley Fool AU Releases Five Cheap and Good Stocks to Buy for 2020 and beyond!….
Our experts here at The Motley Fool Australia have just released a fantastic report, detailing 5 dirt cheap shares that you can buy in 2020.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading over 40% off it’s high, all while offering a fully franked dividend yield over 3%…
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click here or the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
More reading
- The ASX big bank stock most likely to outperform in the COVID-19 recovery
- Should you throw $3,000 into Altium shares today?
- 3 ASX shares to instantly diversify your portfolio
- Are ASX 200 travel shares in the buy zone?
- Is the Bega Cheese share price a strong ASX buy today?
Cathryn Goh has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The post Cochlear share price edges lower on patent infringement news appeared first on Motley Fool Australia.
from Motley Fool Australia https://ift.tt/3bL7b8e
Leave a Reply